Clinical Trials Sponsored by Lynkcell Europe

Total 2711 results

Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Effect of ASP1707 on the Bodies of Healthy Male Subjects After a Single Dose of Radioactive ASP1707

Pharmacokinetics of ASP1707

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Investigate the Appearance and Disappearance of ASP3652 in Blood and Spinal Fluid in Healthy Male Subjects

Healthy Subjects | Pharmacokinetics of ASP3652 | Pharmacodynamics of ASP3652

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects

Healthy Subjects | Pharmacokinetics | Mild and Moderate Hepatic Impairment

Slovakia
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Systemic Pharmacokinetics, Metabolism and Excretion Routes of YM178 in Man, After Administration of Radio-labeled YM178

Metabolic Processes

Netherlands
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Effect of Multiple Doses of Gemfribozil on a Single Dose of ASP3652, and to Assess the Effects of Multiple Doses of ASP3652 on a Single Dose of Repaglinide in the Body of Healthy Subjects

Healthy Subjects | Drug-Drug Interaction (DDI)

United Kingdom
Astellas Pharma Europe Ltd.

Completed

Vesitirim™ in Men Postmarketing Observational Study (VIM)

Overactive Bladder (OAB) | Lower Urinary Tract Symptoms (LUTS)

Ireland
Astellas Pharma Europe B.V.

Completed

Absolute Bioavailability Study With Ipragliflozin

Healthy Subjects | Bioavailability of Ipragliflozin

United Kingdom
Southern Europe New Drug Organization
Celgene Corporation

Unknown

Lenalidomide and Paclitaxel in Advanced Solid Tumors

Advanced Solid Tumors

Switzerland, Italy
Southern Europe New Drug Organization
Bayer; Novartis

Suspended

Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets

Advanced Solid Tumors

Italy
Southern Europe New Drug Organization
Novartis Pharmaceuticals

Completed

LBH Phase II in Small Cell Lung Cancer (SCLC)

Small Cell Lung Carcinoma

Germany, Italy
Kringle Pharma Europe AB
Kringle Pharma, Inc.

Unknown

Phase I/II Dose Ranging CHRONSEAL® Study in Venous Leg Ulcers

Chronic Venous Leg Ulcers

Norway, Sweden
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate FK778 in Kidney Transplant Patients

Kidney Transplantation | Renal Transplantation | Transplantation, Kidney | Grafting, Kidney | Transplantation, Renal

Belgium, Germany, Spain, Sweden, Italy, Switzerland, United Kingdom, Austria, France, Poland, Czech Republic, Netherlands
Institut de cancérologie Strasbourg Europe
UR 3072

Recruiting

Characterization and Kinetic of Chemotherapy-induced Cardiovascular Toxicity in Breast Cancer (PROTECT-COEUR)

Breast Cancer

France
CytoSorbents Europe GmbH
BRAHMS GmbH; MedInnovation GmbH

Recruiting

A RCT to Assess the Performance of CytoSorb for Shock Reversal in Patients With Vasoplegic Septic Shock (PROCYSS)

Septic Shock

Germany
Astellas Pharma Europe Ltd.

Active, not recruiting

Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®

Liver Transplantation | Kidney Transplantation | Heart Transplantation | Lung Transplantation | Intestine Transplantation

Belgium, Czechia, France, Germany, Italy, Poland, United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Survey About Trade-offs When Choosing Menopause Treatments

Moderate to Severe Vasomotor Symptoms

United Kingdom
Merit Medical Systems, Inc.
Meditrial Europe Ltd.

Completed

Evaluation of the Surfacer System Approach to Central Venous Access (SAVEUS)

Venous Occlusion

United States
Astellas Pharma Europe Ltd.

Completed

A Survey About Hot Flashes in Women Going Through the Menopause

Vasomotor Symptoms | Menopause

United Kingdom
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder

Overactive Bladder | Pharmacokinetics of Mirabegron | Neurogenic Detrusor Overactivity

Belgium, Denmark, Norway, Poland, Serbia
Astellas Pharma Europe B.V.

Completed

A Study of MA-0217 (ASP1128) in Healthy Adult Subjects and Healthy Elderly Subjects

Healthy Volunteers

United States
Astellas Pharma Europe B.V.

Completed

A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis (SERENITY)

Interstitial Cystitis | Bladder Pain Syndrome

Spain, Russian Federation, Belgium, Czechia, Germany, Hungary, Latvia, Netherlands, Poland, United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Non-Interventional Study to Evaluate Time to Event and Healthcare Resource Utilisation for Prostate Cancer Participants Throughout the Disease Trajectories Until Progression or Death

Prostate Cancer

Sweden
Cardiovascular and Interventional Radiological...

Completed

CIRSE Registry for SIR-Spheres Therapy (CIRT)

Liver Carcinoma

Austria
Seven Dreamers Europe SAS
Slb Pharma; nastent.inc

Completed

Efficacy, Safety and Acceptability of Nastent™ in Snoring and Obstructive Sleep Apnea

Snoring | Obstructive Sleep Apnea

France
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease

Healthy Subjects | Type 2 Diabetes Mellitus (T2DM) | Chronic Kidney Disease (CKD) | Pharmacokinetics of ASP8232 | Pharmacodynamics of ASP8232

Bulgaria, Moldova, Republic of, Romania
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME) (VIDI)

Diabetes Mellitus | Diabetic Macular Edema

United States
Medtronic Endovascular
Medtronic - MITG; Meditrial Europe Ltd.

Completed

Rapid Renal Sympathetic Denervation for Resistant Hypertension (RAPID)

Hypertension, Resistant to Conventional Therapy

Netherlands, Germany, Belgium, Italy, Luxembourg, New Zealand
Astellas Pharma Europe B.V.

Completed

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder (SYNERGY II)

Overactive Bladder | Urgency Incontinence | Urinary Bladder Overactive | Urinary Bladder Diseases\Urologic Diseases

Belgium, Russian Federation, Korea, Republic of, United States, Germany, Spain, Australia, Bulgaria, Canada, Czechia, Denmark, Estonia, Finland, Hungary, Italy, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, ... and more
Astellas Pharma Europe B.V.

Completed

Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms (Neptune II)

Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia

Belgium, Italy, France, Austria, United Kingdom, Netherlands, Poland, Slovakia, Belarus, Germany, Czechia
F2G Biotech GmbH
Bio-Kinetic Europe, Ltd.

Withdrawn

Drug/Drug Interactions With F901318

Invasive Aspergillosis
Astellas Pharma Europe B.V.

Completed

A Phase 1 Study to Investigate the Mechanism of Action of Ipragliflozin

Type 2 Diabetes Mellitus

Germany
Astellas Pharma Europe B.V.

Completed

Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms (Neptune)

Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia

Belgium, Italy, France, Austria, United Kingdom, Netherlands, Hungary, Russian Federation, Poland, Slovakia, Czech Republic, Belarus, Germany
Astellas Pharma Europe B.V.

Completed

Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder (Blossom)

Urinary Bladder, Overactive

Belgium, Czech Republic, Germany, Spain, Sweden, United Kingdom
Astellas Pharma Europe B.V.

Completed

An Observational Study Looking at How Well the Drug Eligard Works and How Well it is Tolerated by the Body of Patients With Advanced Prostate Carcinoma in the Russian Federation

Advanced Prostate Carcinoma

Russian Federation
Astellas Pharma Europe Ltd.

Completed

Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food

Herpes Zoster | Herpes Genitalis

France
Astellas Pharma Europe B.V.

Completed

A Combined Single and Multiple Ascending Dose Study of ASP6858 in Healthy Subjects

Healthy Volunteers

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery (ONYX-3)

Venous Thromboembolism | Arthroplasty, Replacement, Hip

Denmark, Spain, United States, Austria, Colombia, Russian Federation, India, Italy, United Kingdom, Germany, Hungary, Estonia, Romania, South Africa, Israel, Poland, Sweden, Canada, Australia, Lithuania, Ukraine, Latvia, Finland, Brazil, Slovak... and more
Astellas Pharma Europe B.V.

Completed

A Study to Investigate the Effect of Oral Doses of Pilocarpine on Salivary Secretion and Static Pupillometry in Healthy Subjects

Healthy Subjects

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability and Effects of Single and Multiple Ascending Doses of ASP1707 in Healthy Male and Pre-menopausal Female Subjects, Including a Comparison of the Effects Under Fasted and Fed Conditions in Healthy Young Male Subjects

Pharmacokinetics of ASP1707 | Pharmacodynamics of ASP1707

France
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR) (SOLAR)

Overactive Bladder | Urinary Incontinence | Urge Incontinence

France, Belgium, Spain, Turkey, Australia, Russian Federation, Hungary, Italy, Netherlands, Poland, Czech Republic
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate Whether Verapamil Has an Effect on the Uptake and Elimination of Solifenacin and Tamsulosin When Administered in a Combination Tablet

Healthy Subjects | Drug-Drug Interaction (DDI)

France
Astellas Pharma Europe B.V.

Completed

A Study to Compare the Amount of Drug in the Blood After a Single Tablet EC905 Containing Solifenacin and Tamsulosin is Taken by Healthy Males Compared to Separate Tablets of Solifenacin and Tamsulosin

Healthy Subjects | Pharmacokinetics | EC905

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Pharmacokinetics, Metabolism and Excretion Routes of ASP3652 in Man, After Administration of 14C Radio Labeled ASP3652

Healthy Subjects | Pharmacokinetics of ASP3652

United Kingdom
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)

Overactive Bladder

Poland, United Kingdom, Germany, Spain, Netherlands, Belgium, Czech Republic, Italy, Norway, Hungary, Sweden, Denmark, Greece, France, Russian Federation
Astellas Pharma Europe B.V.

Completed

A Study to Compare the Actions in the Body of Healthy Subjects of Three Modified Release Formulations of YM178 Under Fasted and Fed Conditions With One Immediate Release Formulation of YM178 Under Fasted Conditions

Healthy Subjects | Pharmacokinetics of YM178

Netherlands
Astellas Pharma Europe B.V.

Completed

A Study to Find Out How YM150 is Absorbed Into and Eliminated From the Body in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics

Netherlands
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)

Thromboembolism

Italy, Spain, Sweden, Austria, Denmark, Russian Federation, Poland, Bosnia and Herzegovina, Serbia, Norway, Latvia, Finland, Lithuania, Czech Republic, Germany, Slovakia, Greece
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability and Effects of Single Ascending Doses of ASP3652 in Healthy Subjects

Healthy Subjects | Pharmacokinetics | Pharmacodynamics | Safety

Netherlands
Lynx Health Science GmbH
Meditrial Europe Ltd.

Recruiting

Feasibility Study for Instant Cardiac Diagnostic and Post-operative Risk Assessment With the LynxPatch Device (LP-I-CARDIAG)

Heart Diseases | Cardiovascular Diseases

Germany
ExThera Medical Europe BV
University Hospital, Essen

Not yet recruiting

Reduction of BK Viremia in Kidney Transplant Patients (CP026)

Kidney Diseases | Kidney Transplant Infection | Kidney Transplant; Complications

Germany

Clinical Trials Sponsored by Lynkcell Europe

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations